Clinical development for treatment of any cancer histotype.

• DeMethAVaxTM alone
• DeMethAVaxTM in combination with immune checkpoint blocking antibodies (Ab)
• DeMethAVaxTM in combination with DNA Hypomethylating Agent (DHA)
• DeMethAVaxTM in combination with immune checkpoint blocking Ab and DHA